Forma Therapeutics penned an $815 million oncology drug discovery alliance with BI. BMS and Amgen spent over $1 billion each to purchase Inhibitex and Micromet, respectively. And AngioDynamics acquired Navilyst Medical for $367 million. Biopharma and device financing both increased in January from the previous month.
Exhibit 1
Top Alliances In January 2012
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
